Abstract

Mean S-TK1 activities were 1.11 +/- 0.46 pmol/min/mL in healthy dogs and 1.15 +/- 0.32 pmol/min/mL in healthy humans. S-TK1 activities in dogs with hematological malignancies were 24.2 +/- 47.9 pmol/min/mL, and the receiver operating characteristic curve showed an area under the curve of 0.88. With a cut-off value of 1.9 pmol/min/mL (mean value +/- 2 SD), the sensitivity was 0.94 and the specificity was 0.68. Very similar results were obtained with human samples (healthy and lymphoma cases). S-TK1 activities measured during chemotherapy of six dogs with lymphoma were drastically reduced. In one case, S-TK1 activity increased prior to relapse. S-TK1 levels in dogs with solid tumors did not differ from the healthy group. S-TK1 activities correlated with those determined with the TK-REA and TK-Liaison assays (r = 0.92 and r = 0.96, respectively). In conclusion, this optimized [H-3]-dThd assay is fast, sensitive and economical for measuring S-TK1 activity and should increase its clinical use as biomarker. (C) 2012 Elsevier Ltd. All rights reserved.

Keywords

Thymidine kinase 1; Canine; Lymphoma; Radioenzymatic method; Biomarker; Prognosis

Published in

Veterinary Journal
2012, volume: 194, number: 1, pages: 40-47
Publisher: ELSEVIER SCI LTD

Authors' information